However, the main advantage of this analysis is that pooling of data from the three studies included here allowed an evaluation of the efficacy and safety of DA when administered at baseline Hb ≤10 g/dL in patients with Stage IV cancer, in the absence of trial data addressing this important clinical question. Here, GSTM1 is linked to cancer.